真核延伸因子2激酶是治疗肿瘤的潜在新靶标  

Eukaryotic elongation factor 2 kinase is a potential new target for the treatment of tumors

作　　者：李阳 朱蕾[1] LI Yang;ZHU Lei(Department of Pharmacology,Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC,Beijing 100005,China)

机构地区：[1]中国医学科学院基础医学研究所,北京协和医学院基础学院药理系,北京100005

出　　处：《基础医学与临床》2024年第7期1039-1043,共5页Basic and Clinical Medicine

基　　金：中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-005);中央高水平医院临床科研业务费(2022-PUMCH-C-025)。

摘　　要：真核延伸因子2激酶(eEF2K)是一种Ca^(2+)/CaM依赖性蛋白激酶,通过磷酸化底物eEF2,从而抑制eEF2的活性阻止蛋白质的合成,促进肿瘤细胞增殖、侵袭、转移并调节肿瘤微环境。该eEF2K属于非典型蛋白激酶家族的“α-激酶”成员,与典型的蛋白激酶在序列上同源性小,靶向eEF2K可以避免因对大多数激酶影响而产生的毒副作用,因此被认为是肿瘤靶向治疗的潜在分子靶标。Eukaryotic elongation factor 2 kinase(eEF2K)is a Ca^(2+)/CAM⁃dependent protein kinase,which inhib⁃its the activity of substrate eEF2 by phosphorylating eEF2 to prevent protein synthesis,promote tumor cell prolifera⁃tion,invasion,metastasis and to regulate tumor microenvironment.The eEF2K is“α⁃kinase”member of the atypi⁃cal protein kinase family and has little sequence homology with typical protein kinases.Targeting eEF2K can avoid the toxic side effects caused by most kinases,so it is considered as a potential molecular target for tumor targeted therapy.

关 键 词：eEF2K 肿瘤微环境 肿瘤治疗 抑制剂 

分 类 号：R966[医药卫生—药理学]